2022 World Conference on Lung Cancer (ePosters)-EP01.07-001. Surveillance with FDG PET/CT after Completion of Therapy for NSCLC: A Status Update on Inclusion in the SUPE

EP01.07-001. Surveillance with FDG PET/CT after Completion of Therapy for NSCLC: A Status Update on Inclusion in the SUPE_R Trial

Back to course

Pdf Summary

The SUPE_R trial is a study that aims to determine if surveillance of non-small cell lung cancer (NSCLC) patients with FDG PET/CT and ctDNA sequencing can improve detection of cancer recurrence and increase the number of treatable relapses. The trial protocol involves recruiting patients from all regions of Denmark, obtaining a baseline blood sample for ctDNA analysis before therapy, and randomizing patients to either standard surveillance or surveillance with FDG PET/CT every 6 months for two years or until recurrence.<br /><br />Patient enrollment for the trial began in 2018 and the goal of including 750 randomized patients was met in November 2021. As of July 2022, 48.7% of randomized patients have completed the intervention. A total of 923 patients were enrolled in part 1 and 319 patients were included in part 2 without prior inclusion in part 1. The baseline characteristics of patients included in part 1 are listed in Table 1.<br /><br />However, the trial revealed that 53.3% of patients included in part 1 were not randomized for part 2. The reasons for dropout prior to randomization are listed in Table 2. The proportion of patients not randomized was higher for those with more advanced disease at diagnosis.<br /><br />In conclusion, the enrollment in the SUPE_R trial has been completed after three years of patient recruitment. However, it is noteworthy that a significant portion of patients included in part 1 were not randomized for part 2, and this proportion was higher for patients with more advanced disease. The impact of this dropout on the outcome of the trial is yet to be explored.

Asset Subtitle

Kasper Guldbrandsen

Meta Tag

Speaker Kasper Guldbrandsen

Topic Early Detection and Screening - Work Up

Keywords

SUPE_R trial

non-small cell lung cancer

NSCLC

FDG PET/CT

ctDNA sequencing

cancer recurrence

treatable relapses

surveillance

randomization

patient enrollment